Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

Incyte and Genesis Therapeutics have agreed to discover and optimize at least two initial small molecule compounds through Genesis’s AI platform, Genesis Exploration of Molecular Space (GEMS).

This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and ...

Shares of Incyte Corp. INCY shed 1.56% to $70.16 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.24% to 6,144.15 and the ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...